Key statistics dashboard for Bolt Biotherapeutics, Inc. (BOLT). Valuation multiples (P/E, P/B, EV/EBITDA), profitability margins, financial-health ratios, per-share metrics and stock-level data in one consolidated view — the snapshot quantitative analysts and value investors check first.
Bolt Biotherapeutics, Inc. is a biotechnology company currently conducting clinical trials, focused on developing innovative immuno-oncology therapies. Its mission is to create agents that equip the body's immune system to identify and eliminate cancerous cells. A key therapeutic in its pipeline is BDC-1001, an investigational treatment targeting the human epidermal growth factor receptor 2 (HER2).
Stock Data
| Price | $3.63 |
| Market Cap | $7M |
| Enterprise Value | $15.7M |
| Beta | 0.86 |
| Exchange | NASDAQ |
| Country | US |
Valuation Multiples
| P/E Ratio | -0.25 |
| Price / Book | 0.54 |
| P/S | 1.65 |
| EV/EBITDA | -0.57 |
| EV/Sales | 3.35 |
| EV/FCF | -0.50 |
| P/FCF | -0.25 |
| Earnings Yield | -468.32% |
| FCF Yield | -452.11% |
| Dividend Yield | 0.00% |
Profitability
| Gross Margin | 95.68% |
| EBIT Margin | -611.47% |
| EBITDA Margin | -591.91% |
| Operating Margin | -623.04% |
| Net Margin | -611.47% |
| Return on Equity | -126.23% |
| Return on Assets | -71.23% |
| Return on Invested Capital | -82.33% |
| Return on Capital Employed | -90.17% |
Financial Health
| Current Ratio | 2.61 |
| Quick Ratio | 2.61 |
| Cash Ratio | 1.63 |
| Debt / Equity | 1.71 |
| Debt / Assets | 53.60% |
| Net Debt / EBITDA | -0.32 |
| Interest Coverage | 0.00 |
| Piotroski F-Score | 4 |
| Altman Z-Score | -12.58 |
Per-Share Data
| Revenue per share | 2.78 |
| Book Value per share | 7.48 |
| Cash per share | 10.41 |
| FCF per share | -18.65 |
| Tangible Book Value per share | 7.48 |
| Dividend per share | 0.00 |
Analyst Consensus
| Strong Buy | 0 |
| Buy | 3 |
| Hold | 5 |
| Sell | 0 |
| Strong Sell | 0 |
| Total analysts | 8 |
| Avg rating (1-5) | 0.38 |
Related companies: AEON · CING · CLRB · EVGN · IMNN · INAB · LYRA
Explore sector: Healthcare · Biotechnology
More sections of BOLT: Overview · Financials · Valuation · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks